Mitochondrial apoptosis and BH3 mimetics [version 1; referees: 3 approved]

Mitochondrial apoptosis and BH3 mimetics [version 1; referees: 3 approved]

The BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances i...

Full description

Bibliographic Details
Main Authors: Haiming Dai, X. Wei Meng, Scott H. Kaufmann
Format: Article
Language:English
Published: F1000 Research Ltd 2016-12-01
Series:F1000Research
Subjects:
Cancer Therapeutics
Cell Signaling
Cellular Death & Stress Responses
Immunopharmacology & Hematologic Pharmacology
Leukemia & Proliferative Disorders of Hematic Cells
Membranes & Sorting
Pediatric Hematology
Pediatric Oncology
Online Access:https://f1000research.com/articles/5-2804/v1
id doaj-82afa4c14b1641aba5f3ca3068b3ba7b
record_format Article
spelling doaj-82afa4c14b1641aba5f3ca3068b3ba7b2020-11-25T02:53:51ZengF1000 Research LtdF1000Research2046-14022016-12-01510.12688/f1000research.9629.110375Mitochondrial apoptosis and BH3 mimetics [version 1; referees: 3 approved]Haiming Dai0X. Wei Meng1Scott H. Kaufmann2Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USADepartment of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USADepartment of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USAThe BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances in understanding of the biology of BCL2 family members that shed light on the action of BH3 mimetics, review preclinical and clinical studies leading to the regulatory approval of venetoclax, and discuss future investigation of this new class of antineoplastic agent.https://f1000research.com/articles/5-2804/v1Cancer TherapeuticsCell SignalingCellular Death & Stress ResponsesImmunopharmacology & Hematologic PharmacologyLeukemia & Proliferative Disorders of Hematic CellsMembranes & SortingPediatric HematologyPediatric Oncology
collection DOAJ
language English
format Article
sources DOAJ
author Haiming Dai
X. Wei Meng
Scott H. Kaufmann
spellingShingle Haiming Dai
X. Wei Meng
Scott H. Kaufmann
Mitochondrial apoptosis and BH3 mimetics [version 1; referees: 3 approved]
F1000Research
Cancer Therapeutics
Cell Signaling
Cellular Death & Stress Responses
Immunopharmacology & Hematologic Pharmacology
Leukemia & Proliferative Disorders of Hematic Cells
Membranes & Sorting
Pediatric Hematology
Pediatric Oncology
author_facet Haiming Dai
X. Wei Meng
Scott H. Kaufmann
author_sort Haiming Dai
title Mitochondrial apoptosis and BH3 mimetics [version 1; referees: 3 approved]
title_short Mitochondrial apoptosis and BH3 mimetics [version 1; referees: 3 approved]
title_full Mitochondrial apoptosis and BH3 mimetics [version 1; referees: 3 approved]
title_fullStr Mitochondrial apoptosis and BH3 mimetics [version 1; referees: 3 approved]
title_full_unstemmed Mitochondrial apoptosis and BH3 mimetics [version 1; referees: 3 approved]
title_sort mitochondrial apoptosis and bh3 mimetics [version 1; referees: 3 approved]
publisher F1000 Research Ltd
series F1000Research
issn 2046-1402
publishDate 2016-12-01
description The BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances in understanding of the biology of BCL2 family members that shed light on the action of BH3 mimetics, review preclinical and clinical studies leading to the regulatory approval of venetoclax, and discuss future investigation of this new class of antineoplastic agent.
topic Cancer Therapeutics
Cell Signaling
Cellular Death & Stress Responses
Immunopharmacology & Hematologic Pharmacology
Leukemia & Proliferative Disorders of Hematic Cells
Membranes & Sorting
Pediatric Hematology
Pediatric Oncology
url https://f1000research.com/articles/5-2804/v1
work_keys_str_mv AT haimingdai mitochondrialapoptosisandbh3mimeticsversion1referees3approved
AT xweimeng mitochondrialapoptosisandbh3mimeticsversion1referees3approved
AT scotthkaufmann mitochondrialapoptosisandbh3mimeticsversion1referees3approved
_version_ 1724723977069264896

Similar Items